País: Reino Unido
Língua: inglês
Origem: VMD (Veterinary Medicines Directorate)
Carprofen
Norbrook Laboratories Limited
QM01AE91
Carprofen
Tablet
POM-V - Prescription Only Medicine – Veterinarian
Dogs
Anti Inflammatory NSAID
Expired
2009-08-05
Revised: August 2014 AN. 00392/2013 Page 1 of 5 SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Carprogesic 100 mg Tablets for Dogs. (UK, AT, BE, DE, EL, FR, IE, LU, NL, PT, ES) Profenacarp 100 mg Tablets for Dogs. (IT) 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains: Active Ingredient: Carprofen 100 mg Excipients: Tartrazine (E102) 1.2 mg For the full list of excipients, see Section 6.1 3. PHARMACEUTICAL FORM Tablet A yellow circular tablet of 8 mm diameter, embossed “100” on one side and a single breakline on the other side. The tablets can be divided into halves. 4. CLINICAL PARTICULARS 4.1 _TARGET SPECIES:_ Dogs 4.2 _INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES:_ In the dog: Reduction of inflammation and pain caused by musculoskeletal disorders and degenerative joint disease. As a follow up to parenteral analgesia in the management of post operative pain. 4.3 _CONTRAINDICATIONS:_ Do not use in cats. Do not use in pregnant or lactating bitches. Do not use in puppies less than 4 months of age. Do not use in animals with known hypersensitivity to the active substance or to any of the excipients Revised: August 2014 AN. 00392/2013 Page 2 of 5 Do not use in dogs suffering from cardiac, hepatic or renal disease, where there is a possibility of gastrointestinal ulceration or bleeding, or where there is evidence of a blood dyscrasia. 4.4 _SPECIAL WARNINGS FOR EACH TARGET SPECIES:_ Refer to Sections 4.3 and 4.5. 4.5 _SPECIAL PRECAUTIONS FOR USE:_ SPECIAL PRECAUTIONS FOR USE IN ANIMALS Use in aged dogs may involve additional risk. If such a use cannot be avoided, such dogs may require a reduced dosage and careful clinical management. Avoid use in any dehydrated, hypoproteinemic, hypovolaemic or hypotensive dog, as there is a potential risk of increased renal toxicity. NSAIDs can cause inhibition of phagocytosis and hence in the treatment of inflammatory conditions associated with bacterial infection, appropriate concurrent antimicrobial therapy should be instiga Leia o documento completo